Kodiak Sciences is a clinical-stage biopharmaceutical company focused on therapies for retinal diseases such as wet age-related macular degeneration and diabetic eye disease. Its pipeline includes late-stage candidates designed for durable treatment of high-prevalence retinal vascular conditions. The company has no commercial product revenue and depends on advancing drug candidates through clinical development and regulatory review.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -57.5 | — |
| Q2 2025 | 0 | — | -54.3 | — |
| Q3 2025 | 0 | — | -61.5 | — |
| Q4 2025 | 0 | — | -56.7 | — |
| Q1 2026 | 0 | — | -58.2 | — |
| Q2 2026 | 0 | — | -65.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Octave Intelligence plc (OCTV), StepStone Group Inc. (STEP), Impinj, Inc. (PI), ACI Worldwide, Inc. (ACIW), Merit Medical Systems, Inc. (MMSI), Laureate Education, Inc. (LAUR)